Structure via PubChem · Public domain (PubChem)
rivastigmine
Sign in to saveAlso known as ENA713, Ena 713 free base, Exelon®, (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate, m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 464382904
- Drug.image
- Rivastigmine ACS.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Rivastigmine 3D xtal ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 260
- Drug.tradename
- Exelon, others
- Drug.MedlinePlus
- a602009
- Drug.DailyMedID
- Rivastigmine
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- By mouth, transdermal
- Drug.class
- Acetylcholinesterase inhibitor
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- DA03
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C14H22N2O2
- Molecular weight
- 250.34 g/mol
- IUPAC name
- [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
- SMILES
- CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
- InChIKey
- XSVMFMHYUFZWBK-NSHDSACASA-N
- XLogP
- 2.3
- Polar surface area
- 32.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
2,581 papers- Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.PloS one · 2024
- Rivastigmine for treatment-refractory posttraumatic stress disorder: a systematic review.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan · 2024
- Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.Clinical interventions in aging · 2008
- Rivastigmine for Alzheimer's disease.Expert review of neurotherapeutics · 2005
- Update on rivastigmine.The neurologist · 2003
via PubMed
Wikidata facts
- Mass
- 250.168128
- Has use
- medication
Show 9 more facts
- defined daily dose
- 9
- chemical formula
- C₁₄H₂₂N₂O₂
- medical condition treated
- Alzheimer's disease
- isomeric SMILES
- CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
- canonical SMILES
- CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
- World Health Organisation international non-proprietary name
- rivastigmine
- Commons category
- Rivastigmine
- physically interacts with
- butyrylcholinesterase
- significant drug interaction
- levobunolol
Sources (9)
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Efficacy
- Side effects
- Administration
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- References
Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
Rivastigmine is eliminated through the urine, and appears to have relatively few drug-drug interactions.
Excerpted from Wikipedia’s “rivastigmine” article, available under the CC BY-SA 4.0 licence.